Please use this identifier to cite or link to this item:
Title: Efficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial
Authors: Thianboonsong T.
Kanokrungsee S.
Paichitrojjana A.
Udompataikul M.
Kamanamool N.
Rojhirunsakool S.
Keywords: aluminum chloride
aluminum salt
aluminum sesquichlorohydrate
antiperspirant agent
non prescription drug
unclassified drug
clinical article
clinical evaluation
clinical observation
comparative effectiveness
controlled study
disease severity assessment
double blind procedure
drug efficacy
drug safety
drug tolerability
follow up
hyperhidrosis disease severity score
low level laser therapy
patient satisfaction
prospective study
randomized controlled trial
skin disease assessment
sweating intensity visual scale
therapy effect
topical treatment
treatment response
Issue Date: 2020
Abstract: This study evaluated the efficacy and tolerability of topical aluminum sesquichlorohydrate (AS) when compared to aluminum chloride (AC) as a treatment for primary axillary hyperhidrosis (PAH). Twenty subjects were included in this randomized, controlled, split-side 8-week study. All participants applied 20% AS and 20% AC lotions in their axillae (one treatment per axilla) every night for 2 weeks; next, the application was reduced to three times a week for 4 weeks. The assessment was performed using the sweating intensity visual scale (SIVS), hyperhidrosis disease severity score (HDSS), patient satisfaction score, and the appearance of adverse effects on weeks 0, 1, 2, 4, 6, and 8. Both AS as well as AC application showed positive results, significantly differing from the baseline, as assessed using SIVS, HDSS, and patient satisfaction score at every follow-up visit; however, no significant difference was observed between the AS and AC groups at any follow-up visit. The mean time of response was 1.14 weeks for both treatments. A side effect was observed in one subject (5%), who reported itching on the AC axilla. The therapeutic effects persisted even after reducing the frequency of application and lasted for at least 2 weeks after cessation of use. In conclusion, topical 20% AS demonstrated similar efficacy to topical 20% AC in the treatment of PAH, with a high safety profile. © 2020 Wiley Periodicals LLC.
ISSN: 13960296
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.